摘要
目的 结合新冠肺炎疫情的发展,对照美国紧急使用授权制度,收集和分析我国在应对突发公共卫生事件中与医药产品应急审批使用有关政策,探讨适合中国国情的药品紧急使用相关管理建议,以期为将来制修订相关法律法规提供参考。方法 查阅有关政策法规文献,并对应急态势下中美两国的相关政策法规进行分析研究。结果与结论 美国紧急使用授权法律几经修订,相对比较完善。中国更侧重于应急审批,紧急使用授权相对缺失,需加以完善并制度化。
Abstract
OBJECTIVE To collect and analyze some policies used for expedited review of medical products in dealing with public health emergencies in China and discuss administrative proposals for medical products emergency use, which are suitable in China, for offering a reference for amending related laws and regulations in the future. METHODS Relative policies and regulation and literatures are consulted, relative policies in China and U.S were analyzed. RESULTS AND CONCLUSION In U.S. The Emergency Use Authorization had been amended time after time, which is comparatively completed. In China expedited review of medical products were valued, other than emergency use authorization, which needed to be institutionalized.
关键词
突发公共卫生事件 /
紧急使用授权 /
责任豁免
{{custom_keyword}} /
Key words
public health emergency /
emergency use authorization /
liability protection
{{custom_keyword}} /
仲宣惟, 韩若斯, 李波.
中美应对突发公共卫生事件医药产品应急政策分析与思考[J]. 中国药学杂志, 2020, 55(23): 1979-1984 https://doi.org/10.11669/cpj.2020.23.013
ZHONG Xuan-wei, HAN Ruo-si, LI Bo.
The Analysis and Consideration for Emergency Policies of Medical Products Used for Dealing with Public Health Emergency in China and US[J]. Chinese Pharmaceutical Journal, 2020, 55(23): 1979-1984 https://doi.org/10.11669/cpj.2020.23.013
中图分类号：
R95
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] CONGRESS. Project BioShield Act of 2004(Public Law 108-276) [EB/OL]. (2004-07-21) [2020-03-19]. http: / /www. gpo. gov /fdsys /pkg /PLAW-108publ276 /pdf /PLAW-108publ276.pdf.
[2] FDA. Emergency Use Authorization of Medical Products and Related Authorities [EB/OL]. (2018-10-17)[2020-03-19]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authorities.
[3] 113th Congress. Public Law 113-5. Pandemic and All-Hazards Preparedness Reauthorization Act of 2013. (PAHPRA). [EB/ OL]. (2013-03-13) [2020-03-19]. https://www.govinfo.gov/content/pkg/PLAW-113publ5/pdf/PLAW-113publ5.pdf.
[4] FDA. FOOD AND DRUGS [EB/ OL]. (1997-11-21) [2020-03-19]. https://www.govinfo.gov/content/pkg/USCODE-2010-title21/pdf/USCODE-2010-title21-chap9-subchapV-partE-sec360bbb-3.pdf.
[5] FDA. Emergency Use Authorization of Medical Products and Related Authorities [EB/OL]. (2017-07)[2020-03-19]. https://www.fda.gov/media/97321/download.
[6] CONGRESS. 21st Century Cures Act(PUBLIC LAW 114-255)[EB/OL]. (2016-12-13) [2020-03-20]. https://www.congress.gov/114/plaws/publ255/PLAW-114publ255.pdf.
[7] FDA. FEDERAL FOOD, DRUG, AND COSMETIC ACT. (2020-03-27) [2020-03-28]. https://www.fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act.
[8] YAO L X, QIN J, YAN J Y, et al. Emergency use authorization of medical products[J]. Chin J New Drugs(中国新药杂志),2013,22(4): 393-401.
[9] FDA. Emergency Use Authorization[EB /OL]. (2020-06-26) [2020-06-26]. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization.
[10] The National People's Congress of the People's Republic of China. The Law of the people's Republic of China on Vaccine administration[EB /OL]. (2019-07-02) [2020-03-10]. http: //www.nmpa.gov.cn/WS04/CL2076/338648.html.
[11] YANG Y. How to estabilish the foundation of Emergency Use Authorization of Medical Products[N]. China Pharmaceutical New(中国医药报),2019-09-24(003).
[12] CFDA. National Food and Drug Administration National Special approval procedures of Medical Products[EB/OL]. 2005-11-18) [2020-03-10]. https://www.nmpa.gov.cn/yaopin/ypfgwj/ypfgbmgzh/20051118010101724.html.
[13] CFDA. Notice on the issuance of the procedures of emergency approval for medical products and devices [EB /OL]. (2009-08-28) [2020-03-10]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjylqx/20090828120001149.html.
[14] CMDE. The latest summary of emergency review and approval products[EB /OL]. (2020-06-12) [2020-06-26]. https://mp.weixin.qq.com/s/lAcSGKnPs-iOrHF2XK1Wcg.
[15] PRC. The Peoples Republic of China Notice on the implementation of Emergency Regulations for Irradiation and Sterilization of Medical Disposable Protective Clothing (temporary) during the epidemic [EB/OL]. (2020-02-08) [2020-06-26]. http://www.gov.cn/xinwen/2020-02/08/content_5476127.htm.
[16] LI L, JIAO H. Fully guarantee the supply and quality and safety of drugs and medical devices for epidemic prevention and control [EB /OL]. (2020-04-01) [2020-04-06]. http://www.qstheory.cn/dukan/qs/2020-04/01/c_1125791125.htm.
[17] SUN Y. Consideration on drug review and approval policies related to public health emergencies[J]. Drug Eval Res(药物评价研究),2020,43(3):402-411.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1046 KB)
